ProCE Banner Activity

A Walk in the PARP: Remodeling the Landscape of Newly Diagnosed Advanced Ovarian Cancer (With Italian Subtitles)

Multimedia
Watch this on-demand webcast capturing a live CCO webinar featuring expert presentations on the latest data on PARP inhibitors and how to integrate them into your clinical practice for optimal treatment of patients with newly diagnosed advanced ovarian cancer. Features Italian subtitles!

Released: April 29, 2021

Expiration: April 28, 2022

No longer available for credit.

Share

Faculty

Alexandra Leary

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Frederik Marmé

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca

Learning Objectives

  • Assess recent clinical data on the safety and efficacy of PARP inhibitors for the frontline treatment of ovarian cancer
  • Recognize PARP inhibitor–related toxicities and define supportive management strategies to minimize these adverse events
  • Discuss ongoing clinical research evaluating the role of PARP inhibitors in combination with chemotherapy, targeted therapy, and immunotherapy as frontline therapy for ovarian cancer to aid referral for clinical trial participation

Faculty Disclosure

Primary Author

Alexandra Leary, MD, PhD

Co director
Medical Oncologist and Team Leader
Gynecology Translational Research Lab
Department of Medicine
Gustave Roussy Cancer Center
Paris, France

Alexandra Leary, MD, PhD, has disclosed that she has received funds for research support from AstraZeneca.

Frederik Marmé, MD, PhD

Assistant Professor of Gynecology
Division of Gynecologic Oncology
Medical Faculty of Heidelberg
University of Heidelberg
Heidelberg, Germany

Frederik Marmé, MD, PhD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Celgene, Clovis, CureVac, Eisai, Genomic Health, Immunomedics, Janssen-Cilag, Lilly, Merck Sharp & Dohme, Novartis, Pfizer, Roche, Tesaro, and Vaccibody.

Staff Disclosure

Staff

Katie Eustace, MBA

Senior Director, Global Medical Education, Europe

Katie Eustace, MBA, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Tanja Link, PhD

Editorial Contributor

Tanja Link, PhD, has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy Quill, PhD, has no relevant conflicts of interest to report.

Justine Stanley, MSc

Editorial Contributor

Justine Stanley, MSc, has no relevant conflicts of interest to report.